Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index; 13 of the 35 sources its claims cite were checked for support.
Abstract
Drug-induced liver injury (DILI) continues to be a major source of clinical attrition, precautionary warnings, and post-market withdrawal of drugs. Accordingly, there is a need for more predictive tools to assess hepatotoxicity risk in drug discovery. Three-dimensional (3D) spheroid hepatic cultures have emerged as promising tools to assess mechanisms of hepatotoxicity, as they demonstrate enhanced liver phenotype, metabolic activity, and stability in culture not attainable with conventional two-dimensional hepatic models. Increased sensitivity of these models to drug-induced cytotoxicity has been demonstrated with relatively small panels of hepatotoxicants. However, a comprehensive evaluation of these models is lacking. Here, the predictive value of 3D human liver microtissues (hLiMT) to identify known hepatotoxicants using a panel of 110 drugs with and without clinical DILI has been assessed in comparison to plated two-dimensional primary human hepatocytes (PHH). Compounds were treated long-term (14 days) in hLiMT and acutely (2 days) in PHH to assess drug-induced cytotoxicity over an 8-point concentration range to generate IC 50 values. Regardless of comparing IC 50 values or exposure-corrected margin of safety values, hLiMT demonstrated increased sensitivity in identifying known hepatotoxicants than PHH, while specificity was consistent across both assays. In addition, hLiMT out performed PHH in correctly classifying hepatotoxicants from different pharmacological classes of molecules. The hLiMT demonstrated sufficient capability to warrant exploratory liver injury biomarker investigation (miR-122, HMGB1, α -GST) in the cell-culture media. Taken together, this study represents the most comprehensive evaluation of 3D spheroid hepatic cultures up to now and supports their utility for hepatotoxicity risk assessment in drug discovery.
Overview
CoChat Summary
TL;DR
In a 110-drug retrospective panel, 3D human liver microtissues (hLiMT) detected more cytotoxicity IC50 values and showed greater sensitivity than plated 2D primary human hepatocytes (PHH) for identifying clinical DILI-positive compounds, with similar specificity. The hLiMT model also supported exploratory liver-injury biomarker measurement in culture supernatant.
Key findings
- hLiMT detected more IC50 values than PHH across the 110-drug set: 56/110 vs 40/110. Among DILI-positive compounds, no IC50 was determined for 33% (23/69) in hLiMT vs 54% (37/69) in PHH.
- At fixed IC50 thresholds, hLiMT sensitivity was higher at every threshold: at 10 μM, 18.8% (13/69) vs 4.3% (3/69); at 100 μM, 60.9% (42/69) vs 33.3% (23/69). Specificity at 100 μM was 85.4% for both assays; PLR was 4.16 for hLiMT vs 2.28 for PHH, and NLR was 0.46 vs 0.78.
- Using margin-of-safety (MOS = IC50/total plasma Cmax) thresholds, hLiMT again showed higher sensitivity: at 10× MOS, 36.2% (25/69) vs 20.3% (14/69), with specificity 97.6% for both and PLR 14.86 vs 8.32. At 100× MOS, sensitivity was 59.4% vs 40.6%, with specificity 80.5% vs 85.4%.
- hLiMT better distinguished some structurally related pairs: bosentan and sitaxsentan had MOS values of 12.5× and 8.7×, while ambrisentan was not detected; PHH detected no IC50 for any of the three endothelin-receptor antagonists. Exploratory biomarkers α-GST, HMGB1, and miR-122 were measurable in hLiMT supernatant after chlorpromazine exposure.
Methods
- A panel of 110 marketed drugs was classified into five DILI severity categories; categories 1–3 were considered DILI-positive (69 drugs) and categories 4–5 DILI-negative (41 drugs).
- Cytotoxicity was assessed by ATP-based CellTiter-Glo: plated 2D PHH were treated for 48 h, while 3D hLiMT (primary human hepatocytes co-cultured with non-parenchymal cells) were treated for 14 days with re-dosing; IC50 values were generated over an 8-point concentration range and exposure-corrected MOS values were calculated using total plasma Cmax.
- Predictive performance was evaluated with ROC analysis, fixed IC50 and MOS thresholds, Cohen’s kappa, and positive/negative likelihood ratios; reproducibility was tested across different NPC and hepatocyte lots, and exploratory biomarkers were measured in hLiMT culture media.
Limitations
- The paper states that hLiMT failed to properly classify approximately 40% of DILI-positive compounds; no cytotoxicity was observed for 23/69 DILI-positive drugs, and 28/69 DILI-positive compounds fell above a 100× MOS threshold. Many misclassified compounds were associated with low-incidence or idiosyncratic DILI.
- The paper notes that the hLiMT spheroids contain only approximately 1000 cells, which could limit sensitivity for secondary supernatant endpoints, although exploratory biomarkers were detected. It also states that it remained unclear whether enhanced predictive value was due to culture complexity, treatment duration, or other factors.
- Evident from the text: the ROC comparison using only compounds with IC50 values was biased by the different numbers of IC50 values obtained between assays, so the authors relied on fixed practical thresholds; these thresholds are somewhat arbitrary and assay performance depended on the compound set and concentration ranges achievable in vitro.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
9 Valid · 1 Not valid · 15 Not checked · 80 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Increased sensitivity of these models to drug-induced cytotoxicity has been demonstrated with relatively small panels of hepatotoxicants.”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Abstract
What the sources say
- Supportedcites Bell et al. 2016 matched to “Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease” (2016) source
The Discussion reports that long-term dosing enhanced the sensitivity of PHH spheroids to a panel of five hepatotoxins. The Results likewise report increased toxicity and lower EC50 values after prolonged exposure for all five compounds. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These data are in agreement with the findings of Bell et al. (2016) who noted prolonged drug exposure of up to 28 days resulted in increased sensitivity for detection of DILI compounds amiodarone, bosentan, diclofenac, fialuridine, and tolcapone (Bell et al. 2016).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Bell et al. 2016 matched to “Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease” (2016) source
The Results section (‘PHH spheroids are a suitable system to study chronic DILI’) reports testing all five named compounds after 48 hours, 8 days, and 28 days; prolonged exposure increased toxicity and reduced EC50 values for all five. The Discussion likewise describes enhanced sensitivity with long-term dosing. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, the potential of the 3D hLiMT to report on the release of novel translational in vivo liver hepatotoxicity biomarkers, miR-122, a highly liver specific microRNA (Wang et al. 2009), HMGB1, a marker of immune modulation and necrosis (Antoine et al. 2009), and α-GST, a sensitive, highly specific and early biomarker for hepatocellular injury (Muller and Dieterle 2009), following exposure”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Wang et al. 2009 matched to “Circulating microRNAs, potential biomarkers for drug-induced liver injury” (2009) source
The citation is attached specifically to the description of miR-122 as a highly liver-specific microRNA, not to the claim about the 3D hLiMT. The paper’s “Dose-and Duration-Dependent Changes on the Circulating miRNA” section says that miR-122 is highly restricted to the liver. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Antoine et al. 2009 matched to “High-Mobility Group Box-1 Protein and Keratin-18, Circulating Serum Proteins Informative of Acetaminophen-Induced Necrosis and Apoptosis In Vivo” (2009) source
- Not checked — no full text of the sourcecites Muller and Dieterle 2009 matched to “Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring” (2009) source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Addition of extracellular bile acids in the cell-culture media caused increased cytotoxicity of liver spheroid cultures relative to normal media treated spheroid cultures treated with bosentan over 14 day (Hendriks et al. 2016).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Hendriks et al. 2016 matched to “Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability” (2016) source
The Results section reports greater toxicity with bosentan plus bile acids than with bosentan alone in PHH and HepaRG spheroids. Its prolonged-exposure subsection says this synergistic toxicity was more pronounced after 14 days; the Discussion explicitly includes bosentan among the compounds tested over that period. The indexed passages provide no page numbers. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Based on the optimized thresholds for both IC50 and MOS values, both PHH and hLiMT exhibited similar sensitivity for detection of known DILI causing drugs, with values between 63 and 72% (data not shown).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing ROC assessments
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
55 more claims
Create a free account to see all 105 claims and every source verdict.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This was almost double the sensitivity of 3D hepatic spheroids for the same drug set (42%) based on previously published data31,47,48”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“a preclinical model that is currently widely used in pharma and was only able to correctly identify 8 out of the 19 toxic drugs in the set (Table 5).”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the toxicities of these 8 drugs have been shown to be poorly predicted by hepatic spheroids31,32.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas the 3D hepatic spheroids did (only 67% specificity)31”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proctor et al. (Proctor et al., 2017) showed that liver microtissues combining hepatocytes with HSCs, Kupffer, and endothelial cells outperformed 2D systems (87% sensitivity, 92% specificity) and better reflected clinical DILI data.”
From A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis (2026) · cites this paper as Proctor et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Introduction
“Using drug-induced cytotoxicity as an endpoint, hLiMT assay experienced increased sensitivity and specificity to identify known human hepatotoxicants in relation to plated PHH.”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 3D hLiMT IC50 [μM] | 69 | 41 | 13 | 38 | 3 | 56 | 10 | 18.8 | 92.7 | 2.57 | 0.88 | 0.091 | 0.097 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 2D PHH IC50 [μM] | 69 | 41 | 23 | 35 | 6 | 46 | 100 | 33.3 | 85.4 | 2.28 | 0.78 | 0.176 | 0.014 |”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 2D PHH MOS (IC50/C max) | 69 | 41 | 23 | 35 | 6 | 46 | 50× | 33.3 | 85.4 | 2.28 | 0.78 | 0.156 | 0.031 |”
Citations
Cites
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398 · cited 1×
“In addition, the concordance of each assay with known DILI status was assessed using Cohen’s Kappa (Cohen 1960).”
MethodConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 3×
“…etiologies that encompass DILI (Chalasani et al. 2008), with unknown factors driving patient susceptibility towards hepatic stress and injury (Chalasani and Bjornsson 2010), coupled with the poor concordance of preclinical species to identify human hepatotoxicants in vivo (Olson et al. 2000).”
BackgroundStatistics Notes: Diagnostic tests 2: predictive values
Altman, D. G., & Bland, J. M. (1994) · BMJ · doi:10.1136/bmj.309.6947.102 · Cited by 1,711
Diagnostic tests 4: likelihood ratios
Deeks, J. J., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.329.7458.168 · Cited by 1,600 · cited 1×
“In addition, these parameters can be calculated directly from sensitivity and specificity estimates for tests that have binary results (Altman and Bland 1994a; Deeks and Altman 2004).”
BackgroundGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · cited 1×
“In most cases, these systems displayed enhanced metabolic activity, hepatocellular phenotype, and stability in culture, previously not attainable with traditional hepatic cell line or hepatocyte models [refer to review (Godoy et al. 2013)].”
BackgroundSelf-citationMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 4×
“…demonstrated increased CYP450 activity and improved stability of liver phenotype over time in culture compared to monocultures of primary hepatocytes (Khetani and Bhatia 2008), which was hypothesized to be driving in part the increased sensitivity towards hepatotoxicants (Khetani et al. 2013).”
BackgroundInfluentialCirculating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149 · cited 2×
“In addition, the potential of the 3D hLiMT to report on the release of novel translational in vivo liver hepatotoxicity biomarkers, miR-122, a highly liver specific microRNA (Wang et al. 2009), HMGB1, a marker of immune modulation and necrosis (Antoine et al.”
BackgroundDeterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting
Ma, X., Qu, X., Zhu, W., Li, Y.-S., Yuan, S., Zhang, H., Liu, J., Wang, P., Lai, C. S. E., Zanella, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524510113 · Cited by 872 · cited 1×
“…fibroblasts (Khetani and Bhatia 2008; Khetani et al. 2013), three-dimensional (3D) bioprinted liver tissues comprised of several hepatic cell types (Ma et al. 2016; Nguyen et al. 2016), and 3D spheroid cultures either as mono-culture or co-culture with hepatic non-parenchymal cells (NPC) (Bell et…”
BackgroundChalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755 · cited 3×
“This is not surprising in that DILI is comprised of many different etiologies and mechanisms, including factors that are both compound- and patient-related (Chalasani and Bjornsson 2010; Chalasani et al. 2008).”
BackgroundBell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739 · cited 16×
“2016), and 3D spheroid cultures either as mono-culture or co-culture with hepatic non-parenchymal cells (NPC) (Bell et al. 2016; Messner et al. 2013).”
BackgroundResultInfluential
Cited by
Items 101–200 of 327
Lutter, A., Scholka, J., Richter, H., & Anderer, U. (2017) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-179213 · Cited by 29
“The application of tissue spheroids are expanding, e.g. as in vitro tissue models in research and preclinical studies [17, 18], as in vitro platforms for testing drug effects and delivery systems [19], for cell-based therapies in regenerative medicine [20] or for spheroid-based bioprinting of human…”
Kang, W., Podtelezhnikov, A. A., Tanis, K. Q., Pacchione, S. J., Su, M., Bleicher, K. B., Wang, Z., Laws, G. M., Griffiths, T. G., Kuhls, M. C., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa094 · Cited by 29
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
“Meanwhile, compared with PHHs monolayer culture, PHHs spheroids show moderate sensitivity and high specificity after treatment with hepatotoxic drugs, and long-term exposure improves the sensitivity of detecting DILI-positive drugs [103, 104].”
BackgroundChen, X., Kemas, A. M., Mickols, E., Klein, K., Artursson, P., & Lauschke, V. M. (2024) · Biotechnology Journal · doi:10.1002/biot.202300587 · Cited by 33
“Furthermore, liver spheroids have been well characterized as model systems for the prediction of toxicity [16,17] and clearance [18–20] where they outperform previous culture systems, such as sandwich or suspension cultures.”
BackgroundEmerging In Vitro Systems to Screen and Predict Drug-Induced Kidney Toxicity
Nieskens, T. T. G., & Sjogren, A.-K. M. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.12.009 · Cited by 29
Schofield, C. A., Walker, T. M., Taylor, M. A., Patel, M., Vlachou, D. F., Macina, J. M., Vidgeon-Hart, M., Williams, A., McGill, P., Newman, C. F., et al. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00227 · Cited by 31
State-of-the-art advancements in Liver-on-a-chip (LOC): Integrated biosensors for LOC
Liu, M., Xiang, Y., Yang, Y., Long, X., Xiao, Z., Nan, Y., Jiang, Y., Qiu, Y., Huang, Q., & Ai, K. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114758 · Cited by 28
Development of an AI model for DILI-level prediction using liver organoid brightfield images
Tan, S., Ding, Y., Wang, W., Rao, J., Cheng, F., Zhang, Q., Xu, T., Hu, T., Hu, Q., Ye, Z., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08205-6 · Cited by 26
“Speci fi cally, our model successfully identi fi ed simvastatin and stavudine as “ non-No-DILI ” cases, which had been poorly predicted by hepatic spheroids in a previousstudy 24 .”
Translating in vitro to in vivo and animal to human
Steger‐Hartmann, T., & Raschke, M. (2020) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2020.02.003 · Cited by 33
Toxicogenomics of drug induced liver injury – from mechanistic understanding to early prediction.
Lauschke, V. M. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1894571 · Cited by 29
Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
Cavaco, M. C., Fraga, P., Valle, J., Andreu, D., Castanho, M. A. R. B., & Neves, V. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111863 · Cited by 32
Brecklinghaus, T., Albrecht, W., Kappenberg, F., Duda, J., Vartak, N., Edlund, K., Marchan, R., Ghallab, A., Cadenas, C., Günther, G., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109728 · Cited by 32
“Therefore, several previous studies, including our own, used cytotoxicity of cultured hepatocytes as a readout to determine hepatotoxicity in humans [1,4,7].”
ResultSelf-citationCox, B., Barton, P., Class, R., Coxhead, H., Delatour, C., Gillent, E., Henshall, J., Isin, E. M., King, L. M., & Valentin, J. (2022) · Biomaterials and Biosystems · doi:10.1016/j.bbiosy.2022.100054 · Cited by 34
“[4] Proctor WR, Foster AJ, Vogt J, Summers C, Middleton B, Pilling MA, Shienson D, Kijanska M, Ströbel S, Kelm JM, Morgan P, Messner S, Williams D.”
BackgroundThe assessment of the potential hepatotoxicity of new drugs by in vitro metabolomics
Quintás‐Cardama, A., Castell, J. V., & Moreno‐Torres, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1155271 · Cited by 29
“In a previous study, MTs had already been characterized and validated for predicting DILI which demonstrated to be superior to cytotoxicity results in conventional 2D PHHs cell cultures (Proctor et al., 2017).”
BackgroundKohara, H., Bajaj, P., Yamanaka, K., Miyawaki, A., Harada, K., Miyamoto, K., Matsui, T., Okai, Y., Wagoner, M. P., & Shinozawa, T. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz229 · Cited by 26
Cuvellier, M., Rose, S., Ezan, F., Jarry, U., Oliveira, H., Bruyère, A., Rochelle, C. D. L., Legagneux, V., Langouët, S., & Baffet, G. (2022) · Biofabrication · doi:10.1088/1758-5090/ac7825 · Cited by 25
“This superiority of 3D models to maintain hepatocyte-specific functions warrants their use to study the biotransformation of xenobiotics [8, 10–12] and is generating increasing interest in biotechnology developments for drug safety or efficacy prescreening tests and for regulatory purposes as an…”
Segovia‐Zafra, A., Paz, M. V., Serras, A. S., Matilla‐Cabello, G., Bodoque-García, A., Zeo-Sánchez, D. E. D., Niu, H., Álvarez‐Álvarez, I., Sanz‐Villanueva, L., Godec, S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.026 · Cited by 25
Fäs, L., Chen, M., Tong, W., Wenz, F., Hewitt, N. J., Tu, M., Sanchez, K., Zapiórkowska-Blumer, N., Varga, H., Kaczmarska, K., et al. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae123 · Cited by 27
Docci, L., Parrott, N. J., Krähenbühl, S., & Fowler, S. M. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219831407 · Cited by 25
Liver organoids: updates on generation strategies and biomedical applications
Liu, S., Cheng, C., Zhu, L., Zhao, T., Wang, Z., Yi, X., Yan, F., Wang, X., Li, C., Cui, T., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03865-3 · Cited by 33
Oda, S., Uchida, Y., Aleo, M. D., Koza‐Taylor, P., Matsui, Y., Hizue, M., Marroquin, L. D., Whritenour, J., Uchida, E., & Yokoi, T. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02882-4 · Cited by 25
Liu, J., Li, R., Xue, R., Li, T., Leng, L., Wang, Y., Wang, J., Ma, J., Yan, J., Yan, F., et al. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800110 · Cited by 23
Ackerson, T. J., Amberg, A., Atzrodt, J., Arabeyre‐Fabre, C., Defoßa, E., Dorau, M., Dudda, A., Dwyer, J., Holla, W., Kissner, T., et al. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22345 · Cited by 24
Bentwich, I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103515 · Cited by 22
In vitro cell-based models of drug-induced hepatotoxicity screening: progress and limitation
Mirahmad, M., Sabourian, R., Mahdavi, M. R., Larijani, B. A., & Safavi, M. (2022) · Drug Metabolism Reviews · doi:10.1080/03602532.2022.2064487 · Cited by 24
Chan, R., & Benet, L. Z. (2018) · Toxicology Research · doi:10.1039/c8tx00016f · Cited by 28
Orbach, S. M., Ehrich, M. F., & Rajagopalan, P. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.05.006 · Cited by 21
In-silico approach for drug induced liver injury prediction: Recent advances
Saini, N., Bakshi, S., & Sharma, S. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.06.1216 · Cited by 24
Recent advances in the development of in vitro liver models for hepatotoxicity testing
Lu, S., Zhang, J., Lin, S., Zheng, D., Shen, Y., Qin, J., Li, Y. Y., & Wang, S. (2021) · Bio-Design and Manufacturing · doi:10.1007/s42242-021-00142-7 · Cited by 25
Complex in vitro models positioned for impact to drug testing in pharma: a review
Kang, S., Chen, E. C., Cifuentes, H., Co, J. Y., Cole, G., Graham, J. C., Hsia, I., Kiyota, T., Klein, J. A., Kroll, K. T., et al. (2024) · Biofabrication · doi:10.1088/1758-5090/ad6933 · Cited by 25
“…or mimicking the hepatic sinusoid-like physiology through a perfused liver-on-a-chip configuration augments the metabolic competence/stability and generally enhances the sensitivity to detect compounds associated with drug-induced liver injury (DILI) over 2D conventional approaches [241, 244– 247].”
Toward better drug development: Three-dimensional bioprinting in toxicological research
Szűcs, D., Fekete, Z., Guba, M., Kemény, L. V., Jemnitz, K., Kis, E., & Veréb, Z. (2023) · International Journal of Bioprinting · doi:10.18063/ijb.v9i2.663 · Cited by 27
“Since the geometric localization of cells is crucial for proper function, the spheroid models can be applied in toxicology tests, so they can serve as suitable pharmacological tools[38,46-55].”
BackgroundIntegrated Microphysiological Systems: Transferable Organ Models and Recirculating Flow
Renggli, K., Rousset, N., Lohasz, C., Nguyen, O. T. P., & Hierlemann, A. R. (2019) · Advanced Biosystems · doi:10.1002/adbi.201900018 · Cited by 22
Ide, I., Nagao, E., Kajiyama, S., & Mizoguchi, N. (2019) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2019.1686795 · Cited by 20
Garzel, B., Zhang, L., Huang, S. M., & Wang, H. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190709170256 · Cited by 24
HepaChip-MP – a twenty-four chamber microplate for a continuously perfused liver coculture model
Busche, M., Tomilova, O., Schütte, J., Werner, S., Beer, M., Groll, N., Hagmeyer, B., Pawlak, M., Jones, P. D., Schmees, C., et al. (2020) · Lab on a Chip · doi:10.1039/d0lc00357c · Cited by 19
Sasikumar, S., Chameettachal, S., Kingshott, P., Cromer, B., & Pati, F. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00994 · Cited by 18
Gelatin-Based Hybrid Hydrogel Scaffolds: Toward Physicochemical Liver Mimicry
Carpentier, N., der Meeren, L. V., Skirtach, A. G., Devisscher, L., Vlierberghe, H. V., Dubruel, P., & Vlierberghe, S. V. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00643 · Cited by 19
Hussain, F., Basu, S., Heng, J. J. H., Loo, L., & Zink, D. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02778-3 · Cited by 22
New approach methodologies (NAMs) for drug-induced liver injury (DILI): Where are we now?
Shrimali, S., Chen, M., Li, D., & Tong, W. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104452 · Cited by 19
A large-scale human toxicogenomics resource for drug-induced liver injury prediction
Bergen, V., Kodella, K. R., Srikrishnan, S., Barrandon, O., Anderson, S., Rogers-Grazado, M., Fowler, C. C., Beyene, H., Robichaud, N., Fulton, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65690-3 · Cited by 33
“It outperforms 20+ pre-clinical models in a head-to-head comparisons, including mechanistic assays 16 – 21 , cytotoxicity markers 22 – 27 , physicochemical properties 28 ,bioactivation 29 , BSEP 30 approaches, andthelatest in-silico models 31 – 33 , effectively identifying DILI risks in drugs…”
Assessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity
Wang, Q. L., Cohen, J. D., Yukawa, T., Estrella, H., Leonard, C., Nunes, J., Choi, C., Lewis, L., Baker, K. S., Kuga, K., et al. (2022) · ALTEX · doi:10.14573/altex.2112221 · Cited by 24
“Both Proctor et al. (2017) and Shah et al. (2015) demonstrated that tpCmax alone was a good predictor for potential DILI risk.”
BackgroundA Water‐Soluble, Two‐Photon Probe for Imaging Endogenous Hypochlorous Acid in Live Tissue
Xing, P., Feng, Y., Niu, Y., Li, Q., Zhang, Z., Dong, L., & Wang, C. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800249 · Cited by 17
Microfabrication of liver and heart tissues for drug development
Brown, G. E., & Khetani, S. R. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0225 · Cited by 19
A microvascularized in vitro liver model for disease modeling and drug discovery
Bonanini, F., Dinkelberg, R., Torregrosa, M. C., Kortekaas, N., Hagens, T. M. S., Treillard, S., Kurek, D., van Duinen, V., Vulto, P., & Bircsak, K. M. (2024) · Biofabrication · doi:10.1088/1758-5090/ad818a · Cited by 24
Better science for safer medicines: the human imperative
Archibald, K., Tsaioun, K., Kenna, J. G., & Pound, P. (2018) · Journal of the Royal Society of Medicine · doi:10.1177/0141076818812783 · Cited by 20
Nudischer, R., Renggli, K., Hierlemann, A. R., Roth, A. B., & Bertinetti‐Lapatki, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235745 · Cited by 16
Latest impact of engineered human liver platforms on drug development
Monckton, C. P., Brown, G. E., & Khetani, S. R. (2021) · APL Bioengineering · doi:10.1063/5.0051765 · Cited by 18
Machine Learning Models for Predicting Liver Toxicity
Liu, J., Guo, W., Sakkiah, S., Ji, Z., Yavaş, G., Zou, W., Chen, M., Tong, W., Patterson, T. A., & Hong, H. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1960-5_15 · Cited by 23
Li, A. P., Ho, M.-C. D., Amaral, K. B., & Loretz, C. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079657 · Cited by 16
A guide to pathophysiology, signaling pathways, and preclinical models of liver fibrosis
Sultana, M., Islam, M. A., Khairnar, R., & Kumar, S. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112448 · Cited by 16
Matsui, T., Miyamoto, K., Yamanaka, K., Okai, Y., Pfeiffer, E. R., Harada, K., Wagoner, M. P., & Shinozawa, T. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114761 · Cited by 15
Popp, T., Balszuweit, F., Schmidt, A., Eyer, F., Thiermann, H., & Steinritz, D. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104921 · Cited by 19
Assessment of liver injury potential of investigational medicines in drug development
Chalasani, N., Hayashi, P. H., Luffer, D. R., Regev, A., & Watkins, P. B. (2025) · Hepatology · doi:10.1097/hep.0000000000001281 · Cited by 17
Issues with Cancer Spheroid Models in Therapeutic Drug Screening
Fröhlich, E. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200218094200 · Cited by 14
Predicting drug-induced cholestasis: preclinical models
Petrov, P., Fernández-Murga, M. L., López-Riera, M., Gómez-Lechón, M. J., Castell, J. V., & Jover, R. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1487399 · Cited by 14
“A follow-up work demonstrated that HepaRG is able to sustain an endogenous BA synthesis and secretion activity, comparable with PHH, and that accumulates intracellular BA upon treatment with CsA [100], further pointing the suitability of this line for cholestasis research.”
BackgroundInfluentialUtoh, R., Enomoto, S., Yamada, M., Yamanaka, K., Yajima, Y., Furusawa, K., & Seki, M. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112417 · Cited by 15
Emerging Trends in Information‐Driven Engineering of Complex Biological Systems
Steier, A., Muñiz, A. J., Neale, D. B., & Lahann, J. (2019) · Advanced Materials · doi:10.1002/adma.201806898 · Cited by 16
Vaso, C. O., Bila, N. M., Pandolfi, F., Vita, D. D., Bortolami, M., Bonatti, J. L. C., da Silva, R. A. M., Gonçalves, L. N. C., Tudino, V., Costi, R., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051043 · Cited by 15
“This difference between the sensitivity of the monolayer and three-dimensional cultivation may be related to the expression of some genes and proteins [79,80].”
BackgroundTetsuka, K., Ohbuchi, M., Kawabe, T., Goto, T., Kiyonaga, F., Takama, K., Yamazaki, S., & Fujimori, A. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-01070 · Cited by 15
Predictive in vitro toxicology screening to guide chemical design in drug discovery
Johansson, J., Larsson, M. H., & Hornberg, J. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.08.005 · Cited by 13
Goracci, L., Valeri, A., Sciabola, S., Aleo, M. D., Moritz, W., Lichtenberg, J., & Cruciani, G. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00364 · Cited by 14
Nautiyal, M., Qasem, R. J., Fallon, J. K., Wolf, K., Liu, J., Dixon, D., Smith, P. C., & Mosedale, M. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.105010 · Cited by 14
“, 2018) has facilitated their adoption for preclinical toxicity testing (Proctor et al., 2017; Vorrink et al., 2018) and to study mechanisms of DILI (Bell et al.”
BackgroundAddicks, G. C., Rowan‐Carroll, A., Leingartner, K., Williams, A., Meier, M. J., Lorusso, L., Yauk, C. L., & Atlas, E. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf075 · Cited by 21
“These spheroids represent a co-culture model from 10 diverse human liver donors and consist of metabolically active hepatocytes and Kupffer cells (Proctor et al. 2017).”
Human Liver Organoid Models for Assessment of Drug Toxicity at the Preclinical Stage
Karabicici, M., Akbari, S., Ertem, Ö., Gümüştekin, M., & Erdal, E. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230411100121 · Cited by 12
Roux, S., Cherradi, S., & Duong, H. T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1378371 · Cited by 12
Investigation Into the Role of ERK in Tyrosine Kinase Inhibitor-Induced Neuropathy
Belair, D. G., Sudak, K., Connelly, K., Collins, N. D., Kopytek, S., & Kolaja, K. L. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab033 · Cited by 15
Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety
Jadalannagari, S., & Ewart, L. C. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2328794 · Cited by 15
“Similarly, Proctor et al., compared 3D liver microtissues of PHH and NPCs with 2D PHH for 110 drugs and demonstrated liver microtissues had increased sensitivity to detect DILI while both platforms had similar specificity [14].”
Cell competition promotes metastatic intestinal cancer through a multistage process
García, A. K., Ledesma-Terrón, M., Λάμπρου, Μ., Vriend, J., van Luyk, M. E., & Suijkerbuijk, S. J. E. (2024) · iScience · doi:10.1016/j.isci.2024.109718 · Cited by 13
Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI
Stern, S., Wang, H., & Sadrieh, N. K. (2023) · Cells · doi:10.3390/cells12111476 · Cited by 13
Perspectives of data science in preclinical safety assessment
Steger‐Hartmann, T., Kreuchwig, A., Wang, K., Birzele, F., Draganov, D. I., Gaudio, S., & Rothfuß, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103642 · Cited by 12
Lee-Montiel, F. T., Laemmle, A., Dumont, L., Lee, C. S., Huebsch, N., Charwat, V., Okochi, H., HANCOCK, M. J., Siemons, B. A., Boggess, S. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.24.112771 · Cited by 11
Design of optimal concentrations for in vitro cytotoxicity experiments
Schürmeyer, L., Peng, C., Albrecht, W., Brecklinghaus, T., Baur, P., Hengstler, J. G., & Schorning, K. (2025) · Archives of Toxicology · doi:10.1007/s00204-024-03893-1 · Cited by 11
“Concentration-dependent cytotoxicity tests are frequently used in toxicology (Vorrink et al. 2018; Brecklinghaus et al. 2022a; Proctor et al 2017; Khetani et al. 2013; Gu et al. 2018).”
TAK-994 mechanistic investigation into drug-induced liver injury
Shinozawa, T., Miyamoto, K., Baker, K. S., Faber, S. C., Flores, R., Uetrecht, J., von Hehn, C., Yukawa, T., Tohyama, K., Kadali, H., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf003 · Cited by 14
“Each of the 38 compounds was found to induce ≥ 50% cellular ATP depletion at or below 100 μ M, a threshold commonly associated with hepatotoxic liability (Proctor et al. 2017).”
Elucidating Molecular Mechanisms of Drug-Induced Hepatotoxicity of Lapatinib
Yu, Q., Ma, L., Norona, L. M., Dragovich, P. S., Wang, J., Wang, S., Chen, Y.-C., Khojasteh, S. C., Kenny, J. R., Dean, B. J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01305 · Cited by 10
In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk
Norona, L. M., Fullerton, A. M., Lawson, C., Leung, L., Brumm, J., Kiyota, T., Maher, J. M., Khojasteh, C., & Proctor, W. R. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02804-4 · Cited by 12
Self-citation3D In Vitro Human Organ Mimicry Devices for Drug Discovery, Development, and Assessment
Rodríguez‐García, A., Oliva, J., Flores, C., & Hosseini, S. (2020) · Advances in Polymer Technology · doi:10.1155/2020/6187048 · Cited by 11
“[34] presents the testing of over 100 different drugs and their cytotoxicity within both 2D and 3D culture systems.”
BackgroundHigh-Throughput Live and Fixed Cell Imaging Method to Screen Matrigel-Embedded Organoids
Ramm, S., Vary, R., Gulati, T., Luu, J., Cowley, K. J., Janes, M. S., Radio, N. M., & Simpson, K. J. (2022) · Organoids · doi:10.3390/organoids2010001 · Cited by 13
“3D models have been found to be more in vivo-like regarding their gene expression and cell behavior [3,4], and more predictive of both in vivo toxicity and therapeutic efficacy [5,6].”
BackgroundKoyama, S., Arakawa, H., Itoh, M., Masuda, N., Yano, K., Kojima, H., & Ogihara, T. (2018) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2125 · Cited by 9
“In addition, various 3D spheroid culture platforms have been proposed, such as the Cell‐able system (Ikeda et al., 2012; Ogihara et al., 2017) and the Hanging Drop System (Proctor et al., 2017).”
MethodChipangura, J. K., Ntamo, Y., Mohr, B. J., & Chellan, N. (2023) · Human & Experimental Toxicology · doi:10.1177/09603271221147884 · Cited by 10
“93 Increased sensitivity of these models to drug-induced cytotoxicity has been demonstrated with relatively small panels of hepatotoxicants.”
BackgroundCherradi, S., Taulet, N., & Duong, H. T. (2023) · In vitro models · doi:10.1007/s44164-023-00057-w · Cited by 11
“To compare the performance between educated spheroids and current pre-clinical models in predicting DILI risk, we extracted the data from the works cited on the right side of the heatmap some drugs such as stavudine or β-estradiol [20].”
MethodTao, F., Hanada, S., Matsushima, K., Arakawa, H., Ishida, N., Kato, Y., Okimura, S., Watanabe, T., & Kojima, N. (2022) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2022.10.006 · Cited by 9
Park, S. Y., Koh, W., & Lee, H. J. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114417 · Cited by 9
Vorgia, E., Lamprousi, M., Denecke, S., Vogelsang, K., Geibel, S., VONTAS, J. G., & Douris, V. (2020) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2020.103510 · Cited by 8
Brecklinghaus, T., Albrecht, W., Duda, J., Kappenberg, F., Gründler, L., Edlund, K., Marchan, R., Ghallab, A., Cadenas, C., Rieck, A., et al. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.08.006 · Cited by 11
Ma, B.-L., Lu, M., Yu, B., & Tian, J. (2018) · RSC Advances · doi:10.1039/c8ra01424h · Cited by 9
Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infection
Moule, M. G., Benjamin, A. B., Burger, M. L., Herlan, C., Lebedev, M., Lin, J. S., Koster, K. J., Wavare, N., Adams, L. G., Bräse, S., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06725-1 · Cited by 10
“Spheroids demonstrate more accurate pharmacokinetics and pharmacodynamics 73,74 , while ALI cultures allow epithelial cells to differentiate into a similar morphology to that observed within human alveoli 75,76 .”
BackgroundIqbal, M. W., Shahab, M., Ullah, Z., Zheng, G., Anjum, İ., Shazly, G. A., Mengistie, A. A., Sun, X., & Yuan, Q. (2025) · Scientific Reports · doi:10.1038/s41598-024-83767-9 · Cited by 11
“Following this, the IC 50 (half maximal inhibitory concentration) values were extracted from the filtered data and dataset was distributed into three categories based on their IC 50 values 35 .”
Klein, J. A., Heidmann, J. D., Kiyota, T., Fullerton, A. M., Homan, K. A., & Co, J. Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1508820 · Cited by 10
Taylor, K., Ram, R., Ewart, L. C., Goldring, C. E., Russomanno, G., Aithal, G. P., Kostrzewski, T. M., Bauch, C., Wilkinson, J. M., Modi, S., et al. (2025) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2025.1536756 · Cited by 12
DILI prediction in drug development: present and future
Uetrecht, J. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2495955 · Cited by 13
“For example, it has been proposed that cytotoxicity in human liver microtissues is more accurate for iDILI risk potential than other in vitro systems [65].”
Abdellaoui-Soussi, F. E., Brusilovsky, M., Buck, E., Bacon, W. C., Dadgar, S., Fullerton, A. M., Durban, V. M., Barrile, R., Helmrath, M. A., Takebe, T., et al. (2025) · Advanced Science · doi:10.1002/advs.202508584 · Cited by 16
A scalable human liver-on-a-chip platform for predictive safety assessment
Kulkarni, G., Chen, L., Sang, J., Seo, J. H., Grall, R., Wang, Y., Gilbride, P., Yuan, Y., Albaum-Getzen, M., McCormack, J., et al. (2025) · Toxicology · doi:10.1016/j.tox.2025.154378 · Cited by 12
Application of high-content screening for the study of hepatotoxicity: Focus on food toxicology
Donato, M. T., & Tolosa, L. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111872 · Cited by 8
Horn, G., Kranawetvogl, T., John, H., Weigel, C., Rauen, U., Worek, F., & Wille, T. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110285 · Cited by 9
Hopf, N. B., Suter‐Dick, L., Huwyler, J., Borgatta, M., Hegg, L., Pamies, D., Paschoud, H., Puligilla, R. D., Reale, E., Werner, S., et al. (2024) · JMIR Research Protocols · doi:10.2196/50300 · Cited by 9
“They are widely used for the assessment of hepatotoxicity [51-55].”
BackgroundIn vitro liver models for toxicological research
Fukunaga, I., & Takebe, T. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2025.101478 · Cited by 8
Olubamiwa, A. O., Qu, Y., Connor, S., Tong, W., Li, D., & Chen, M. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104485 · Cited by 19
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
Bender, A., Thomas, M. C., Scannell, J. W., Shaywitz, D. A., Ghiandoni, G. M., Greener, J. G., Pruteanu, L.-L., Jacobson, R. D., Handa, K., Hirano, M., et al. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01496-2 · Cited by 44
Zhou, Y., Zhong, Y., & Lauschke, V. M. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2461484 · Cited by 9
“Lower predictive accuracies were reported in liver spheroids cultured in undisclosed media compositions (sensitivity 52–61%, specificity 79–85%), likely due to the addition of growth factors in the culture medium, which cause a partial downregulation of drug metabolizing enzymes [87,88].”
Naito, Y., Yoshinouchi, Y., Sorayama, Y., Kohara, H., Kitano, S., Irie, S., & Matsusaki, M. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.11.027 · Cited by 10
Metadata
- Authors
- Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., Morgan, P., Messner, S., & Williams, D.
- Affiliations
- Genentech (US)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Foster, Alison J.
- Venue
- Archives of Toxicology
- Published
- 2017-06-13
- Volume
- 91
- Issue
- 8
- Pages
- 2849-2863
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC5515971
- OpenAlex
- W2625311319
- Cited by
- 328
- References
- 52
- Citations by year
- 2026: 30 · 2025: 49 · 2024: 33 · 2023: 29 · 2022: 33 · 2021: 33 · 2020: 49 · 2019: 35 · 2018: 31 · 2017: 6
- FWCI
- 35.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Archives of Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- drug-induced liver injury, hepatotoxicity prediction, primary human hepatocytes, drug cytotoxicity, IC50, safety margin, liver injury biomarkers, miR-122, HMGB1, alpha-glutathione S-transferase
- MeSH terms
- Humans, Liver, Predictive Value of Tests, Time Factors, Drug Design, Biomarkers, Risk Assessment, Inhibitory Concentration 50, Hepatocytes, Drug Discovery, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.